nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—Gefitinib—Erlotinib—pancreatic cancer	0.357	1	CrCrCtD
Lapatinib—EGFR—pancreatic cancer	0.215	1	CbGaD
Lapatinib—EGFR—Erlotinib—pancreatic cancer	0.0883	0.34	CbGbCtD
Lapatinib—EGFR—Docetaxel—pancreatic cancer	0.0584	0.225	CbGbCtD
Lapatinib—CYP3A5—Tamoxifen—pancreatic cancer	0.0095	0.0365	CbGbCtD
Lapatinib—CYP2C8—Tamoxifen—pancreatic cancer	0.00913	0.0351	CbGbCtD
Lapatinib—CYP3A5—Erlotinib—pancreatic cancer	0.00808	0.0311	CbGbCtD
Lapatinib—CYP2C8—Erlotinib—pancreatic cancer	0.00777	0.0299	CbGbCtD
Lapatinib—CYP2C19—Tamoxifen—pancreatic cancer	0.00766	0.0295	CbGbCtD
Lapatinib—CYP3A5—Irinotecan—pancreatic cancer	0.00729	0.0281	CbGbCtD
Lapatinib—CYP2C8—Fluorouracil—pancreatic cancer	0.00673	0.0259	CbGbCtD
Lapatinib—ABCB1—Tamoxifen—pancreatic cancer	0.00618	0.0238	CbGbCtD
Lapatinib—CYP3A5—Docetaxel—pancreatic cancer	0.00535	0.0206	CbGbCtD
Lapatinib—ABCB1—Gemcitabine—pancreatic cancer	0.00533	0.0205	CbGbCtD
Lapatinib—CYP3A5—Sunitinib—pancreatic cancer	0.00532	0.0205	CbGbCtD
Lapatinib—ABCB1—Erlotinib—pancreatic cancer	0.00526	0.0202	CbGbCtD
Lapatinib—ABCB1—Irinotecan—pancreatic cancer	0.00475	0.0183	CbGbCtD
Lapatinib—CYP3A4—Tamoxifen—pancreatic cancer	0.0037	0.0142	CbGbCtD
Lapatinib—ABCB1—Docetaxel—pancreatic cancer	0.00348	0.0134	CbGbCtD
Lapatinib—ABCB1—Sunitinib—pancreatic cancer	0.00346	0.0133	CbGbCtD
Lapatinib—CYP3A4—Erlotinib—pancreatic cancer	0.00315	0.0121	CbGbCtD
Lapatinib—CYP3A4—Irinotecan—pancreatic cancer	0.00284	0.0109	CbGbCtD
Lapatinib—ABCB1—Doxorubicin—pancreatic cancer	0.00259	0.00997	CbGbCtD
Lapatinib—CYP3A4—Docetaxel—pancreatic cancer	0.00208	0.00802	CbGbCtD
Lapatinib—CYP3A4—Sunitinib—pancreatic cancer	0.00207	0.00798	CbGbCtD
Lapatinib—ERBB2—gall bladder—pancreatic cancer	0.00178	0.173	CbGeAlD
Lapatinib—TAP1—islet of Langerhans—pancreatic cancer	0.0016	0.155	CbGeAlD
Lapatinib—CYP3A4—Doxorubicin—pancreatic cancer	0.00155	0.00598	CbGbCtD
Lapatinib—TAP1—pancreas—pancreatic cancer	0.00112	0.109	CbGeAlD
Lapatinib—PI4KB—islet of Langerhans—pancreatic cancer	0.00109	0.106	CbGeAlD
Lapatinib—PIK3C2B—pancreas—pancreatic cancer	0.00106	0.102	CbGeAlD
Lapatinib—PIK3C2B—Topotecan—Irinotecan—pancreatic cancer	0.000879	0.421	CbGdCrCtD
Lapatinib—ERBB2—pancreas—pancreatic cancer	0.000821	0.0797	CbGeAlD
Lapatinib—PI4KB—pancreas—pancreatic cancer	0.000769	0.0746	CbGeAlD
Lapatinib—ERBB2—Topotecan—Irinotecan—pancreatic cancer	0.000724	0.346	CbGdCrCtD
Lapatinib—ERBB2—digestive system—pancreatic cancer	0.000701	0.0681	CbGeAlD
Lapatinib—Gefitinib—EGFR—pancreatic cancer	0.00063	1	CrCbGaD
Lapatinib—CYP3A5—islet of Langerhans—pancreatic cancer	0.000286	0.0278	CbGeAlD
Lapatinib—CYP2C19—digestive system—pancreatic cancer	0.000218	0.0212	CbGeAlD
Lapatinib—CYP3A5—pancreas—pancreatic cancer	0.000201	0.0195	CbGeAlD
Lapatinib—CYP3A5—digestive system—pancreatic cancer	0.000172	0.0167	CbGeAlD
Lapatinib—ERBB2—Doxorubicin—Epirubicin—pancreatic cancer	0.00017	0.0814	CbGdCrCtD
Lapatinib—PIK3C2B—Azacitidine—Gemcitabine—pancreatic cancer	0.00016	0.0764	CbGdCrCtD
Lapatinib—ERBB2—Epirubicin—Doxorubicin—pancreatic cancer	0.000157	0.0753	CbGdCrCtD
Lapatinib—ABCB1—islet of Langerhans—pancreatic cancer	0.000152	0.0148	CbGeAlD
Lapatinib—CYP3A4—digestive system—pancreatic cancer	0.000129	0.0125	CbGeAlD
Lapatinib—ABCB1—pancreas—pancreatic cancer	0.000107	0.0104	CbGeAlD
Lapatinib—Leukopenia—Fluorouracil—pancreatic cancer	9.72e-05	0.0012	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Sunitinib—pancreatic cancer	9.7e-05	0.00119	CcSEcCtD
Lapatinib—Fatigue—Sunitinib—pancreatic cancer	9.68e-05	0.00119	CcSEcCtD
Lapatinib—Hypersensitivity—Tamoxifen—pancreatic cancer	9.66e-05	0.00119	CcSEcCtD
Lapatinib—Cough—Gemcitabine—pancreatic cancer	9.64e-05	0.00119	CcSEcCtD
Lapatinib—Constipation—Sunitinib—pancreatic cancer	9.6e-05	0.00118	CcSEcCtD
Lapatinib—Renal failure acute—Epirubicin—pancreatic cancer	9.51e-05	0.00117	CcSEcCtD
Lapatinib—Hepatobiliary disease—Docetaxel—pancreatic cancer	9.48e-05	0.00117	CcSEcCtD
Lapatinib—Epistaxis—Docetaxel—pancreatic cancer	9.46e-05	0.00116	CcSEcCtD
Lapatinib—Asthenia—Tamoxifen—pancreatic cancer	9.41e-05	0.00116	CcSEcCtD
Lapatinib—Myalgia—Gemcitabine—pancreatic cancer	9.4e-05	0.00116	CcSEcCtD
Lapatinib—Arthralgia—Gemcitabine—pancreatic cancer	9.4e-05	0.00116	CcSEcCtD
Lapatinib—Hot flush—Epirubicin—pancreatic cancer	9.38e-05	0.00115	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	9.34e-05	0.00115	CcSEcCtD
Lapatinib—Asthenia—Erlotinib—pancreatic cancer	9.31e-05	0.00115	CcSEcCtD
Lapatinib—Menopausal symptoms—Epirubicin—pancreatic cancer	9.3e-05	0.00114	CcSEcCtD
Lapatinib—Pruritus—Tamoxifen—pancreatic cancer	9.28e-05	0.00114	CcSEcCtD
Lapatinib—Anaphylactic shock—Irinotecan—pancreatic cancer	9.25e-05	0.00114	CcSEcCtD
Lapatinib—Myalgia—Fluorouracil—pancreatic cancer	9.24e-05	0.00114	CcSEcCtD
Lapatinib—Infection—Irinotecan—pancreatic cancer	9.19e-05	0.00113	CcSEcCtD
Lapatinib—Gastrointestinal pain—Sunitinib—pancreatic cancer	9.18e-05	0.00113	CcSEcCtD
Lapatinib—Pruritus—Erlotinib—pancreatic cancer	9.18e-05	0.00113	CcSEcCtD
Lapatinib—ABCB1—digestive system—pancreatic cancer	9.13e-05	0.00887	CbGeAlD
Lapatinib—Nervous system disorder—Irinotecan—pancreatic cancer	9.07e-05	0.00112	CcSEcCtD
Lapatinib—Anaphylactic shock—Gemcitabine—pancreatic cancer	9.01e-05	0.00111	CcSEcCtD
Lapatinib—Cardiac failure—Epirubicin—pancreatic cancer	8.99e-05	0.00111	CcSEcCtD
Lapatinib—Diarrhoea—Tamoxifen—pancreatic cancer	8.97e-05	0.0011	CcSEcCtD
Lapatinib—Infection—Gemcitabine—pancreatic cancer	8.95e-05	0.0011	CcSEcCtD
Lapatinib—Abdominal pain—Sunitinib—pancreatic cancer	8.88e-05	0.00109	CcSEcCtD
Lapatinib—Diarrhoea—Erlotinib—pancreatic cancer	8.88e-05	0.00109	CcSEcCtD
Lapatinib—Anaphylactic shock—Fluorouracil—pancreatic cancer	8.86e-05	0.00109	CcSEcCtD
Lapatinib—Connective tissue disorder—Docetaxel—pancreatic cancer	8.85e-05	0.00109	CcSEcCtD
Lapatinib—Nervous system disorder—Gemcitabine—pancreatic cancer	8.84e-05	0.00109	CcSEcCtD
Lapatinib—Anorexia—Irinotecan—pancreatic cancer	8.82e-05	0.00108	CcSEcCtD
Lapatinib—Infection—Fluorouracil—pancreatic cancer	8.8e-05	0.00108	CcSEcCtD
Lapatinib—Renal failure acute—Doxorubicin—pancreatic cancer	8.8e-05	0.00108	CcSEcCtD
Lapatinib—Pain in extremity—Epirubicin—pancreatic cancer	8.78e-05	0.00108	CcSEcCtD
Lapatinib—Skin disorder—Gemcitabine—pancreatic cancer	8.75e-05	0.00108	CcSEcCtD
Lapatinib—Nervous system disorder—Fluorouracil—pancreatic cancer	8.69e-05	0.00107	CcSEcCtD
Lapatinib—Hot flush—Doxorubicin—pancreatic cancer	8.68e-05	0.00107	CcSEcCtD
Lapatinib—Menopausal symptoms—Doxorubicin—pancreatic cancer	8.61e-05	0.00106	CcSEcCtD
Lapatinib—Anorexia—Gemcitabine—pancreatic cancer	8.59e-05	0.00106	CcSEcCtD
Lapatinib—Anorexia—Fluorouracil—pancreatic cancer	8.45e-05	0.00104	CcSEcCtD
Lapatinib—Insomnia—Irinotecan—pancreatic cancer	8.37e-05	0.00103	CcSEcCtD
Lapatinib—Cardiac disorder—Docetaxel—pancreatic cancer	8.35e-05	0.00103	CcSEcCtD
Lapatinib—Vomiting—Tamoxifen—pancreatic cancer	8.34e-05	0.00103	CcSEcCtD
Lapatinib—Cardiac failure—Doxorubicin—pancreatic cancer	8.32e-05	0.00102	CcSEcCtD
Lapatinib—Hypersensitivity—Sunitinib—pancreatic cancer	8.27e-05	0.00102	CcSEcCtD
Lapatinib—Rash—Tamoxifen—pancreatic cancer	8.27e-05	0.00102	CcSEcCtD
Lapatinib—Dermatitis—Tamoxifen—pancreatic cancer	8.26e-05	0.00102	CcSEcCtD
Lapatinib—Vomiting—Erlotinib—pancreatic cancer	8.25e-05	0.00101	CcSEcCtD
Lapatinib—Dyspnoea—Irinotecan—pancreatic cancer	8.25e-05	0.00101	CcSEcCtD
Lapatinib—Headache—Tamoxifen—pancreatic cancer	8.21e-05	0.00101	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	8.21e-05	0.00101	CcSEcCtD
Lapatinib—Rash—Erlotinib—pancreatic cancer	8.18e-05	0.00101	CcSEcCtD
Lapatinib—Dermatitis—Erlotinib—pancreatic cancer	8.17e-05	0.00101	CcSEcCtD
Lapatinib—Angiopathy—Docetaxel—pancreatic cancer	8.17e-05	0.001	CcSEcCtD
Lapatinib—Dehydration—Epirubicin—pancreatic cancer	8.16e-05	0.001	CcSEcCtD
Lapatinib—Insomnia—Gemcitabine—pancreatic cancer	8.15e-05	0.001	CcSEcCtD
Lapatinib—Dyspepsia—Irinotecan—pancreatic cancer	8.14e-05	0.001	CcSEcCtD
Lapatinib—Immune system disorder—Docetaxel—pancreatic cancer	8.13e-05	0.001	CcSEcCtD
Lapatinib—Headache—Erlotinib—pancreatic cancer	8.13e-05	0.001	CcSEcCtD
Lapatinib—Pain in extremity—Doxorubicin—pancreatic cancer	8.12e-05	0.000999	CcSEcCtD
Lapatinib—Mediastinal disorder—Docetaxel—pancreatic cancer	8.11e-05	0.000998	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	8.07e-05	0.000993	CcSEcCtD
Lapatinib—Asthenia—Sunitinib—pancreatic cancer	8.06e-05	0.000991	CcSEcCtD
Lapatinib—Dry skin—Epirubicin—pancreatic cancer	8.04e-05	0.00099	CcSEcCtD
Lapatinib—Decreased appetite—Irinotecan—pancreatic cancer	8.04e-05	0.000989	CcSEcCtD
Lapatinib—Dyspnoea—Gemcitabine—pancreatic cancer	8.03e-05	0.000988	CcSEcCtD
Lapatinib—Insomnia—Fluorouracil—pancreatic cancer	8.01e-05	0.000986	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Irinotecan—pancreatic cancer	7.99e-05	0.000983	CcSEcCtD
Lapatinib—Fatigue—Irinotecan—pancreatic cancer	7.98e-05	0.000981	CcSEcCtD
Lapatinib—Alopecia—Docetaxel—pancreatic cancer	7.95e-05	0.000979	CcSEcCtD
Lapatinib—Pruritus—Sunitinib—pancreatic cancer	7.95e-05	0.000978	CcSEcCtD
Lapatinib—Constipation—Irinotecan—pancreatic cancer	7.91e-05	0.000973	CcSEcCtD
Lapatinib—Dyspnoea—Fluorouracil—pancreatic cancer	7.9e-05	0.000972	CcSEcCtD
Lapatinib—Mental disorder—Docetaxel—pancreatic cancer	7.89e-05	0.00097	CcSEcCtD
Lapatinib—Malnutrition—Docetaxel—pancreatic cancer	7.84e-05	0.000964	CcSEcCtD
Lapatinib—Decreased appetite—Gemcitabine—pancreatic cancer	7.83e-05	0.000964	CcSEcCtD
Lapatinib—Dyspepsia—Fluorouracil—pancreatic cancer	7.8e-05	0.00096	CcSEcCtD
Lapatinib—Nausea—Tamoxifen—pancreatic cancer	7.79e-05	0.000958	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	7.78e-05	0.000957	CcSEcCtD
Lapatinib—Fatigue—Gemcitabine—pancreatic cancer	7.77e-05	0.000956	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	7.74e-05	0.000952	CcSEcCtD
Lapatinib—Constipation—Gemcitabine—pancreatic cancer	7.71e-05	0.000948	CcSEcCtD
Lapatinib—Nausea—Erlotinib—pancreatic cancer	7.71e-05	0.000948	CcSEcCtD
Lapatinib—Decreased appetite—Fluorouracil—pancreatic cancer	7.7e-05	0.000948	CcSEcCtD
Lapatinib—Diarrhoea—Sunitinib—pancreatic cancer	7.68e-05	0.000945	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	7.65e-05	0.000941	CcSEcCtD
Lapatinib—Back pain—Docetaxel—pancreatic cancer	7.58e-05	0.000933	CcSEcCtD
Lapatinib—Gastrointestinal pain—Irinotecan—pancreatic cancer	7.57e-05	0.000931	CcSEcCtD
Lapatinib—Dehydration—Doxorubicin—pancreatic cancer	7.55e-05	0.000929	CcSEcCtD
Lapatinib—Dry skin—Doxorubicin—pancreatic cancer	7.44e-05	0.000916	CcSEcCtD
Lapatinib—Abdominal pain—Irinotecan—pancreatic cancer	7.31e-05	0.0009	CcSEcCtD
Lapatinib—Anaemia—Docetaxel—pancreatic cancer	7.24e-05	0.000891	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	7.16e-05	0.000881	CcSEcCtD
Lapatinib—Vomiting—Sunitinib—pancreatic cancer	7.14e-05	0.000879	CcSEcCtD
Lapatinib—Neutropenia—Epirubicin—pancreatic cancer	7.09e-05	0.000873	CcSEcCtD
Lapatinib—Rash—Sunitinib—pancreatic cancer	7.08e-05	0.000871	CcSEcCtD
Lapatinib—Dermatitis—Sunitinib—pancreatic cancer	7.07e-05	0.00087	CcSEcCtD
Lapatinib—Headache—Sunitinib—pancreatic cancer	7.04e-05	0.000866	CcSEcCtD
Lapatinib—Leukopenia—Docetaxel—pancreatic cancer	7.01e-05	0.000863	CcSEcCtD
Lapatinib—Palpitations—Docetaxel—pancreatic cancer	6.92e-05	0.000852	CcSEcCtD
Lapatinib—Cough—Docetaxel—pancreatic cancer	6.84e-05	0.000841	CcSEcCtD
Lapatinib—Hypersensitivity—Irinotecan—pancreatic cancer	6.82e-05	0.000839	CcSEcCtD
Lapatinib—Pneumonia—Epirubicin—pancreatic cancer	6.8e-05	0.000837	CcSEcCtD
Lapatinib—Infestation NOS—Epirubicin—pancreatic cancer	6.76e-05	0.000832	CcSEcCtD
Lapatinib—Infestation—Epirubicin—pancreatic cancer	6.76e-05	0.000832	CcSEcCtD
Lapatinib—Arthralgia—Docetaxel—pancreatic cancer	6.67e-05	0.000821	CcSEcCtD
Lapatinib—Myalgia—Docetaxel—pancreatic cancer	6.67e-05	0.000821	CcSEcCtD
Lapatinib—Nausea—Sunitinib—pancreatic cancer	6.67e-05	0.000821	CcSEcCtD
Lapatinib—Asthenia—Irinotecan—pancreatic cancer	6.64e-05	0.000817	CcSEcCtD
Lapatinib—Neuropathy peripheral—Epirubicin—pancreatic cancer	6.63e-05	0.000816	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	6.63e-05	0.000815	CcSEcCtD
Lapatinib—Stomatitis—Epirubicin—pancreatic cancer	6.59e-05	0.000811	CcSEcCtD
Lapatinib—Neutropenia—Doxorubicin—pancreatic cancer	6.56e-05	0.000807	CcSEcCtD
Lapatinib—Hypersensitivity—Fluorouracil—pancreatic cancer	6.53e-05	0.000803	CcSEcCtD
Lapatinib—Asthenia—Gemcitabine—pancreatic cancer	6.47e-05	0.000795	CcSEcCtD
Lapatinib—Hepatobiliary disease—Epirubicin—pancreatic cancer	6.4e-05	0.000787	CcSEcCtD
Lapatinib—Anaphylactic shock—Docetaxel—pancreatic cancer	6.4e-05	0.000787	CcSEcCtD
Lapatinib—Epistaxis—Epirubicin—pancreatic cancer	6.38e-05	0.000785	CcSEcCtD
Lapatinib—Pruritus—Gemcitabine—pancreatic cancer	6.38e-05	0.000784	CcSEcCtD
Lapatinib—Infection—Docetaxel—pancreatic cancer	6.35e-05	0.000782	CcSEcCtD
Lapatinib—Diarrhoea—Irinotecan—pancreatic cancer	6.33e-05	0.000779	CcSEcCtD
Lapatinib—Pneumonia—Doxorubicin—pancreatic cancer	6.29e-05	0.000774	CcSEcCtD
Lapatinib—Nervous system disorder—Docetaxel—pancreatic cancer	6.27e-05	0.000772	CcSEcCtD
Lapatinib—Pruritus—Fluorouracil—pancreatic cancer	6.27e-05	0.000771	CcSEcCtD
Lapatinib—Infestation—Doxorubicin—pancreatic cancer	6.26e-05	0.00077	CcSEcCtD
Lapatinib—Infestation NOS—Doxorubicin—pancreatic cancer	6.26e-05	0.00077	CcSEcCtD
Lapatinib—Skin disorder—Docetaxel—pancreatic cancer	6.21e-05	0.000764	CcSEcCtD
Lapatinib—Diarrhoea—Gemcitabine—pancreatic cancer	6.17e-05	0.000759	CcSEcCtD
Lapatinib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	6.13e-05	0.000755	CcSEcCtD
Lapatinib—Stomatitis—Doxorubicin—pancreatic cancer	6.1e-05	0.00075	CcSEcCtD
Lapatinib—Anorexia—Docetaxel—pancreatic cancer	6.1e-05	0.00075	CcSEcCtD
Lapatinib—Diarrhoea—Fluorouracil—pancreatic cancer	6.06e-05	0.000746	CcSEcCtD
Lapatinib—Connective tissue disorder—Epirubicin—pancreatic cancer	5.97e-05	0.000734	CcSEcCtD
Lapatinib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	5.92e-05	0.000728	CcSEcCtD
Lapatinib—Epistaxis—Doxorubicin—pancreatic cancer	5.9e-05	0.000726	CcSEcCtD
Lapatinib—Vomiting—Irinotecan—pancreatic cancer	5.88e-05	0.000724	CcSEcCtD
Lapatinib—Rash—Irinotecan—pancreatic cancer	5.83e-05	0.000718	CcSEcCtD
Lapatinib—Dermatitis—Irinotecan—pancreatic cancer	5.83e-05	0.000717	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	5.83e-05	0.000717	CcSEcCtD
Lapatinib—Headache—Irinotecan—pancreatic cancer	5.8e-05	0.000713	CcSEcCtD
Lapatinib—Insomnia—Docetaxel—pancreatic cancer	5.78e-05	0.000712	CcSEcCtD
Lapatinib—Vomiting—Gemcitabine—pancreatic cancer	5.73e-05	0.000705	CcSEcCtD
Lapatinib—Dyspnoea—Docetaxel—pancreatic cancer	5.7e-05	0.000701	CcSEcCtD
Lapatinib—Rash—Gemcitabine—pancreatic cancer	5.68e-05	0.000699	CcSEcCtD
Lapatinib—Dermatitis—Gemcitabine—pancreatic cancer	5.68e-05	0.000698	CcSEcCtD
Lapatinib—Headache—Gemcitabine—pancreatic cancer	5.65e-05	0.000695	CcSEcCtD
Lapatinib—Cardiac disorder—Epirubicin—pancreatic cancer	5.63e-05	0.000693	CcSEcCtD
Lapatinib—Vomiting—Fluorouracil—pancreatic cancer	5.63e-05	0.000693	CcSEcCtD
Lapatinib—Dyspepsia—Docetaxel—pancreatic cancer	5.63e-05	0.000693	CcSEcCtD
Lapatinib—Rash—Fluorouracil—pancreatic cancer	5.59e-05	0.000687	CcSEcCtD
Lapatinib—Dermatitis—Fluorouracil—pancreatic cancer	5.58e-05	0.000687	CcSEcCtD
Lapatinib—Decreased appetite—Docetaxel—pancreatic cancer	5.56e-05	0.000684	CcSEcCtD
Lapatinib—Headache—Fluorouracil—pancreatic cancer	5.55e-05	0.000683	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	5.52e-05	0.000679	CcSEcCtD
Lapatinib—Connective tissue disorder—Doxorubicin—pancreatic cancer	5.52e-05	0.000679	CcSEcCtD
Lapatinib—Fatigue—Docetaxel—pancreatic cancer	5.51e-05	0.000678	CcSEcCtD
Lapatinib—Angiopathy—Epirubicin—pancreatic cancer	5.51e-05	0.000678	CcSEcCtD
Lapatinib—Nausea—Irinotecan—pancreatic cancer	5.5e-05	0.000676	CcSEcCtD
Lapatinib—Immune system disorder—Epirubicin—pancreatic cancer	5.48e-05	0.000675	CcSEcCtD
Lapatinib—Mediastinal disorder—Epirubicin—pancreatic cancer	5.47e-05	0.000673	CcSEcCtD
Lapatinib—Constipation—Docetaxel—pancreatic cancer	5.47e-05	0.000673	CcSEcCtD
Lapatinib—Alopecia—Epirubicin—pancreatic cancer	5.37e-05	0.00066	CcSEcCtD
Lapatinib—Nausea—Gemcitabine—pancreatic cancer	5.35e-05	0.000659	CcSEcCtD
Lapatinib—Mental disorder—Epirubicin—pancreatic cancer	5.32e-05	0.000654	CcSEcCtD
Lapatinib—Malnutrition—Epirubicin—pancreatic cancer	5.29e-05	0.00065	CcSEcCtD
Lapatinib—Nausea—Fluorouracil—pancreatic cancer	5.26e-05	0.000648	CcSEcCtD
Lapatinib—Gastrointestinal pain—Docetaxel—pancreatic cancer	5.23e-05	0.000643	CcSEcCtD
Lapatinib—Cardiac disorder—Doxorubicin—pancreatic cancer	5.21e-05	0.000641	CcSEcCtD
Lapatinib—Back pain—Epirubicin—pancreatic cancer	5.11e-05	0.000629	CcSEcCtD
Lapatinib—Angiopathy—Doxorubicin—pancreatic cancer	5.1e-05	0.000627	CcSEcCtD
Lapatinib—Immune system disorder—Doxorubicin—pancreatic cancer	5.07e-05	0.000624	CcSEcCtD
Lapatinib—Mediastinal disorder—Doxorubicin—pancreatic cancer	5.06e-05	0.000623	CcSEcCtD
Lapatinib—Abdominal pain—Docetaxel—pancreatic cancer	5.06e-05	0.000622	CcSEcCtD
Lapatinib—Alopecia—Doxorubicin—pancreatic cancer	4.96e-05	0.000611	CcSEcCtD
Lapatinib—Mental disorder—Doxorubicin—pancreatic cancer	4.92e-05	0.000606	CcSEcCtD
Lapatinib—Malnutrition—Doxorubicin—pancreatic cancer	4.89e-05	0.000602	CcSEcCtD
Lapatinib—Anaemia—Epirubicin—pancreatic cancer	4.89e-05	0.000601	CcSEcCtD
Lapatinib—Leukopenia—Epirubicin—pancreatic cancer	4.73e-05	0.000582	CcSEcCtD
Lapatinib—Back pain—Doxorubicin—pancreatic cancer	4.73e-05	0.000582	CcSEcCtD
Lapatinib—Hypersensitivity—Docetaxel—pancreatic cancer	4.71e-05	0.00058	CcSEcCtD
Lapatinib—Palpitations—Epirubicin—pancreatic cancer	4.67e-05	0.000575	CcSEcCtD
Lapatinib—Cough—Epirubicin—pancreatic cancer	4.61e-05	0.000567	CcSEcCtD
Lapatinib—Asthenia—Docetaxel—pancreatic cancer	4.59e-05	0.000565	CcSEcCtD
Lapatinib—Pruritus—Docetaxel—pancreatic cancer	4.52e-05	0.000557	CcSEcCtD
Lapatinib—Anaemia—Doxorubicin—pancreatic cancer	4.52e-05	0.000556	CcSEcCtD
Lapatinib—Arthralgia—Epirubicin—pancreatic cancer	4.5e-05	0.000554	CcSEcCtD
Lapatinib—Myalgia—Epirubicin—pancreatic cancer	4.5e-05	0.000554	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	4.47e-05	0.00055	CcSEcCtD
Lapatinib—Leukopenia—Doxorubicin—pancreatic cancer	4.38e-05	0.000539	CcSEcCtD
Lapatinib—Diarrhoea—Docetaxel—pancreatic cancer	4.38e-05	0.000538	CcSEcCtD
Lapatinib—Palpitations—Doxorubicin—pancreatic cancer	4.32e-05	0.000532	CcSEcCtD
Lapatinib—Anaphylactic shock—Epirubicin—pancreatic cancer	4.31e-05	0.000531	CcSEcCtD
Lapatinib—Infection—Epirubicin—pancreatic cancer	4.29e-05	0.000527	CcSEcCtD
Lapatinib—Cough—Doxorubicin—pancreatic cancer	4.27e-05	0.000525	CcSEcCtD
Lapatinib—Nervous system disorder—Epirubicin—pancreatic cancer	4.23e-05	0.00052	CcSEcCtD
Lapatinib—Skin disorder—Epirubicin—pancreatic cancer	4.19e-05	0.000515	CcSEcCtD
Lapatinib—Arthralgia—Doxorubicin—pancreatic cancer	4.16e-05	0.000512	CcSEcCtD
Lapatinib—Myalgia—Doxorubicin—pancreatic cancer	4.16e-05	0.000512	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	4.13e-05	0.000509	CcSEcCtD
Lapatinib—Anorexia—Epirubicin—pancreatic cancer	4.11e-05	0.000506	CcSEcCtD
Lapatinib—Vomiting—Docetaxel—pancreatic cancer	4.07e-05	0.0005	CcSEcCtD
Lapatinib—Rash—Docetaxel—pancreatic cancer	4.03e-05	0.000496	CcSEcCtD
Lapatinib—Dermatitis—Docetaxel—pancreatic cancer	4.03e-05	0.000496	CcSEcCtD
Lapatinib—Headache—Docetaxel—pancreatic cancer	4.01e-05	0.000493	CcSEcCtD
Lapatinib—Anaphylactic shock—Doxorubicin—pancreatic cancer	3.99e-05	0.000491	CcSEcCtD
Lapatinib—Infection—Doxorubicin—pancreatic cancer	3.97e-05	0.000488	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	3.93e-05	0.000484	CcSEcCtD
Lapatinib—Nervous system disorder—Doxorubicin—pancreatic cancer	3.91e-05	0.000482	CcSEcCtD
Lapatinib—Insomnia—Epirubicin—pancreatic cancer	3.9e-05	0.00048	CcSEcCtD
Lapatinib—Skin disorder—Doxorubicin—pancreatic cancer	3.88e-05	0.000477	CcSEcCtD
Lapatinib—Dyspnoea—Epirubicin—pancreatic cancer	3.85e-05	0.000473	CcSEcCtD
Lapatinib—Anorexia—Doxorubicin—pancreatic cancer	3.8e-05	0.000468	CcSEcCtD
Lapatinib—Nausea—Docetaxel—pancreatic cancer	3.8e-05	0.000467	CcSEcCtD
Lapatinib—Dyspepsia—Epirubicin—pancreatic cancer	3.8e-05	0.000467	CcSEcCtD
Lapatinib—Decreased appetite—Epirubicin—pancreatic cancer	3.75e-05	0.000461	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.72e-05	0.000458	CcSEcCtD
Lapatinib—Fatigue—Epirubicin—pancreatic cancer	3.72e-05	0.000458	CcSEcCtD
Lapatinib—Constipation—Epirubicin—pancreatic cancer	3.69e-05	0.000454	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.64e-05	0.000447	CcSEcCtD
Lapatinib—Insomnia—Doxorubicin—pancreatic cancer	3.61e-05	0.000444	CcSEcCtD
Lapatinib—Dyspnoea—Doxorubicin—pancreatic cancer	3.56e-05	0.000438	CcSEcCtD
Lapatinib—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.53e-05	0.000434	CcSEcCtD
Lapatinib—Dyspepsia—Doxorubicin—pancreatic cancer	3.51e-05	0.000432	CcSEcCtD
Lapatinib—Decreased appetite—Doxorubicin—pancreatic cancer	3.47e-05	0.000427	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.45e-05	0.000424	CcSEcCtD
Lapatinib—Fatigue—Doxorubicin—pancreatic cancer	3.44e-05	0.000423	CcSEcCtD
Lapatinib—Constipation—Doxorubicin—pancreatic cancer	3.41e-05	0.00042	CcSEcCtD
Lapatinib—Abdominal pain—Epirubicin—pancreatic cancer	3.41e-05	0.00042	CcSEcCtD
Lapatinib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3.26e-05	0.000402	CcSEcCtD
Lapatinib—Hypersensitivity—Epirubicin—pancreatic cancer	3.18e-05	0.000391	CcSEcCtD
Lapatinib—Abdominal pain—Doxorubicin—pancreatic cancer	3.16e-05	0.000388	CcSEcCtD
Lapatinib—Asthenia—Epirubicin—pancreatic cancer	3.09e-05	0.000381	CcSEcCtD
Lapatinib—Pruritus—Epirubicin—pancreatic cancer	3.05e-05	0.000375	CcSEcCtD
Lapatinib—Diarrhoea—Epirubicin—pancreatic cancer	2.95e-05	0.000363	CcSEcCtD
Lapatinib—Hypersensitivity—Doxorubicin—pancreatic cancer	2.94e-05	0.000362	CcSEcCtD
Lapatinib—Asthenia—Doxorubicin—pancreatic cancer	2.86e-05	0.000352	CcSEcCtD
Lapatinib—Pruritus—Doxorubicin—pancreatic cancer	2.82e-05	0.000347	CcSEcCtD
Lapatinib—Vomiting—Epirubicin—pancreatic cancer	2.74e-05	0.000337	CcSEcCtD
Lapatinib—Diarrhoea—Doxorubicin—pancreatic cancer	2.73e-05	0.000336	CcSEcCtD
Lapatinib—Rash—Epirubicin—pancreatic cancer	2.72e-05	0.000335	CcSEcCtD
Lapatinib—Dermatitis—Epirubicin—pancreatic cancer	2.72e-05	0.000334	CcSEcCtD
Lapatinib—Headache—Epirubicin—pancreatic cancer	2.7e-05	0.000332	CcSEcCtD
Lapatinib—Nausea—Epirubicin—pancreatic cancer	2.56e-05	0.000315	CcSEcCtD
Lapatinib—Vomiting—Doxorubicin—pancreatic cancer	2.54e-05	0.000312	CcSEcCtD
Lapatinib—Rash—Doxorubicin—pancreatic cancer	2.52e-05	0.00031	CcSEcCtD
Lapatinib—Dermatitis—Doxorubicin—pancreatic cancer	2.51e-05	0.000309	CcSEcCtD
Lapatinib—Headache—Doxorubicin—pancreatic cancer	2.5e-05	0.000308	CcSEcCtD
Lapatinib—Nausea—Doxorubicin—pancreatic cancer	2.37e-05	0.000292	CcSEcCtD
Lapatinib—CYP2C8—Metabolism—GLP1R—pancreatic cancer	4.41e-06	5.97e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	4.36e-06	5.9e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—DPYD—pancreatic cancer	4.34e-06	5.88e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—TGFB1—pancreatic cancer	4.33e-06	5.85e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	4.33e-06	5.85e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—SRC—pancreatic cancer	4.27e-06	5.78e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—KRAS—pancreatic cancer	4.26e-06	5.77e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—MYC—pancreatic cancer	4.26e-06	5.77e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—TGFB1—pancreatic cancer	4.25e-06	5.75e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—HIF1A—pancreatic cancer	4.25e-06	5.75e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—TSC2—pancreatic cancer	4.24e-06	5.74e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AGTR1—pancreatic cancer	4.21e-06	5.7e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—KRAS—pancreatic cancer	4.2e-06	5.68e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—MYC—pancreatic cancer	4.2e-06	5.68e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—TGFB1—pancreatic cancer	4.19e-06	5.67e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NFKBIA—pancreatic cancer	4.19e-06	5.67e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—EGFR—pancreatic cancer	4.17e-06	5.64e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PIK3CB—pancreatic cancer	4.16e-06	5.62e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—STK11—pancreatic cancer	4.15e-06	5.62e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—APOE—pancreatic cancer	4.15e-06	5.61e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—SLC2A2—pancreatic cancer	4.12e-06	5.58e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—NRAS—pancreatic cancer	4.11e-06	5.56e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—EGFR—pancreatic cancer	4.11e-06	5.56e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—SRC—pancreatic cancer	4.11e-06	5.55e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PIK3CB—pancreatic cancer	4.09e-06	5.54e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	4.08e-06	5.52e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—TNF—pancreatic cancer	4.04e-06	5.47e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	4.03e-06	5.46e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—EGF—pancreatic cancer	4.01e-06	5.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—KRAS—pancreatic cancer	4.01e-06	5.42e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CXCL8—pancreatic cancer	3.99e-06	5.4e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	3.97e-06	5.38e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—NRAS—pancreatic cancer	3.95e-06	5.34e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GLP1R—pancreatic cancer	3.94e-06	5.33e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—KRAS—pancreatic cancer	3.94e-06	5.33e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.94e-06	5.33e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CXCL8—pancreatic cancer	3.93e-06	5.32e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—PIK3CA—pancreatic cancer	3.92e-06	5.3e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PIK3CD—pancreatic cancer	3.9e-06	5.28e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PRSS1—pancreatic cancer	3.88e-06	5.25e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—KRAS—pancreatic cancer	3.88e-06	5.25e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—DPYD—pancreatic cancer	3.88e-06	5.25e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—PIK3CA—pancreatic cancer	3.86e-06	5.22e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GLP1R—pancreatic cancer	3.85e-06	5.2e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	3.85e-06	5.2e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NOTCH1—pancreatic cancer	3.83e-06	5.18e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CASP3—pancreatic cancer	3.82e-06	5.17e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—DPYD—pancreatic cancer	3.78e-06	5.12e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CASP3—pancreatic cancer	3.76e-06	5.09e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CDH1—pancreatic cancer	3.73e-06	5.05e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCND1—pancreatic cancer	3.72e-06	5.03e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—EGF—pancreatic cancer	3.7e-06	5.01e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CD44—pancreatic cancer	3.69e-06	4.99e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CTNNB1—pancreatic cancer	3.68e-06	4.98e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—SLC2A2—pancreatic cancer	3.68e-06	4.98e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCND1—pancreatic cancer	3.66e-06	4.96e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.64e-06	4.93e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SMAD4—pancreatic cancer	3.64e-06	4.92e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CTNNB1—pancreatic cancer	3.63e-06	4.91e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HRAS—pancreatic cancer	3.62e-06	4.9e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—PIK3CA—pancreatic cancer	3.62e-06	4.89e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MMP9—pancreatic cancer	3.61e-06	4.89e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PTEN—pancreatic cancer	3.59e-06	4.86e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—SLC2A2—pancreatic cancer	3.59e-06	4.86e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	3.59e-06	4.85e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HRAS—pancreatic cancer	3.57e-06	4.83e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PIK3CD—pancreatic cancer	3.56e-06	4.82e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—PIK3CA—pancreatic cancer	3.56e-06	4.82e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MMP9—pancreatic cancer	3.56e-06	4.81e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HES1—pancreatic cancer	3.55e-06	4.8e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—KRAS—pancreatic cancer	3.54e-06	4.79e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PTEN—pancreatic cancer	3.54e-06	4.79e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GCG—pancreatic cancer	3.53e-06	4.78e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.51e-06	4.75e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—HRAS—pancreatic cancer	3.41e-06	4.61e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PIK3CB—pancreatic cancer	3.4e-06	4.6e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—KRAS—pancreatic cancer	3.4e-06	4.6e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ARG2—pancreatic cancer	3.36e-06	4.55e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—HRAS—pancreatic cancer	3.35e-06	4.53e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—SRC—pancreatic cancer	3.33e-06	4.51e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—STK11—pancreatic cancer	3.32e-06	4.49e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—HRAS—pancreatic cancer	3.3e-06	4.46e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CD—pancreatic cancer	3.29e-06	4.45e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—SRC—pancreatic cancer	3.28e-06	4.44e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CXCL8—pancreatic cancer	3.27e-06	4.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—PIK3CA—pancreatic cancer	3.25e-06	4.4e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	3.25e-06	4.39e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—VEGFA—pancreatic cancer	3.24e-06	4.39e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—STAT3—pancreatic cancer	3.21e-06	4.35e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NRAS—pancreatic cancer	3.2e-06	4.33e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—AKT1—pancreatic cancer	3.2e-06	4.33e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	3.2e-06	4.33e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—VEGFA—pancreatic cancer	3.19e-06	4.32e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CD44—pancreatic cancer	3.19e-06	4.32e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—STAT3—pancreatic cancer	3.16e-06	4.28e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NRAS—pancreatic cancer	3.16e-06	4.27e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—AKT1—pancreatic cancer	3.15e-06	4.27e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	3.13e-06	4.23e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—PIK3CA—pancreatic cancer	3.12e-06	4.23e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TERT—pancreatic cancer	3.11e-06	4.21e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PIK3CB—pancreatic cancer	3.11e-06	4.2e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	3.1e-06	4.19e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GCG—pancreatic cancer	3.06e-06	4.14e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—HRAS—pancreatic cancer	3.01e-06	4.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—AKT1—pancreatic cancer	3.01e-06	4.07e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MYC—pancreatic cancer	2.98e-06	4.04e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TGFB1—pancreatic cancer	2.98e-06	4.03e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HIF1A—pancreatic cancer	2.98e-06	4.03e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TSC2—pancreatic cancer	2.97e-06	4.02e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—AKT1—pancreatic cancer	2.96e-06	4e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TYMP—pancreatic cancer	2.94e-06	3.98e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MYC—pancreatic cancer	2.94e-06	3.98e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TGFB1—pancreatic cancer	2.93e-06	3.97e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—EGFR—pancreatic cancer	2.92e-06	3.95e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—AKT1—pancreatic cancer	2.91e-06	3.94e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—APOE—pancreatic cancer	2.9e-06	3.93e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HRAS—pancreatic cancer	2.89e-06	3.91e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—STK11—pancreatic cancer	2.88e-06	3.89e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—EGFR—pancreatic cancer	2.87e-06	3.89e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CB—pancreatic cancer	2.87e-06	3.88e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—TYMS—pancreatic cancer	2.86e-06	3.87e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CD44—pancreatic cancer	2.85e-06	3.85e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KDR—pancreatic cancer	2.85e-06	3.85e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTGS2—pancreatic cancer	2.84e-06	3.85e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.79e-06	3.77e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CD44—pancreatic cancer	2.78e-06	3.76e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.76e-06	3.74e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KRAS—pancreatic cancer	2.76e-06	3.73e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CTNNB1—pancreatic cancer	2.75e-06	3.73e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GCG—pancreatic cancer	2.73e-06	3.7e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KRAS—pancreatic cancer	2.72e-06	3.67e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NFKBIA—pancreatic cancer	2.71e-06	3.66e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.7e-06	3.65e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PTEN—pancreatic cancer	2.68e-06	3.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NOTCH1—pancreatic cancer	2.68e-06	3.63e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GCG—pancreatic cancer	2.67e-06	3.61e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—AKT1—pancreatic cancer	2.66e-06	3.59e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CG—pancreatic cancer	2.62e-06	3.55e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—NRAS—pancreatic cancer	2.62e-06	3.55e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—EGF—pancreatic cancer	2.59e-06	3.51e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—STK11—pancreatic cancer	2.57e-06	3.47e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—AKT1—pancreatic cancer	2.55e-06	3.45e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CTNNB1—pancreatic cancer	2.54e-06	3.44e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PIK3CA—pancreatic cancer	2.53e-06	3.43e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—STK11—pancreatic cancer	2.51e-06	3.39e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PIK3CA—pancreatic cancer	2.5e-06	3.38e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—SRC—pancreatic cancer	2.49e-06	3.37e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTEN—pancreatic cancer	2.48e-06	3.35e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—TYMS—pancreatic cancer	2.47e-06	3.35e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—pancreatic cancer	2.45e-06	3.32e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—pancreatic cancer	2.41e-06	3.27e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.41e-06	3.26e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—STAT3—pancreatic cancer	2.4e-06	3.25e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NRAS—pancreatic cancer	2.4e-06	3.24e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	2.37e-06	3.21e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—HRAS—pancreatic cancer	2.34e-06	3.17e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—DPYD—pancreatic cancer	2.33e-06	3.15e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—APOE—pancreatic cancer	2.32e-06	3.14e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—HRAS—pancreatic cancer	2.31e-06	3.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CD—pancreatic cancer	2.3e-06	3.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—SRC—pancreatic cancer	2.3e-06	3.11e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—KRAS—pancreatic cancer	2.26e-06	3.05e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—STAT3—pancreatic cancer	2.22e-06	3e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	2.21e-06	2.99e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NRAS—pancreatic cancer	2.21e-06	2.99e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—TYMS—pancreatic cancer	2.21e-06	2.99e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—TYMS—pancreatic cancer	2.16e-06	2.92e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	2.1e-06	2.84e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PIK3CA—pancreatic cancer	2.07e-06	2.8e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—AKT1—pancreatic cancer	2.07e-06	2.8e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—KRAS—pancreatic cancer	2.06e-06	2.79e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MYC—pancreatic cancer	2.06e-06	2.79e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—TGFB1—pancreatic cancer	2.06e-06	2.78e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—AKT1—pancreatic cancer	2.04e-06	2.76e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PPARG—pancreatic cancer	2.02e-06	2.74e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—APOE—pancreatic cancer	2.01e-06	2.72e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CB—pancreatic cancer	2.01e-06	2.72e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL8—pancreatic cancer	1.93e-06	2.61e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—HRAS—pancreatic cancer	1.92e-06	2.6e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.91e-06	2.58e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—KRAS—pancreatic cancer	1.9e-06	2.58e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PIK3CA—pancreatic cancer	1.89e-06	2.56e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CASP3—pancreatic cancer	1.85e-06	2.5e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	1.84e-06	2.49e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	1.82e-06	2.46e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCND1—pancreatic cancer	1.8e-06	2.43e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—APOE—pancreatic cancer	1.8e-06	2.43e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CTNNB1—pancreatic cancer	1.78e-06	2.41e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—APOE—pancreatic cancer	1.75e-06	2.37e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PPARG—pancreatic cancer	1.75e-06	2.37e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HRAS—pancreatic cancer	1.75e-06	2.37e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CA—pancreatic cancer	1.75e-06	2.37e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MMP9—pancreatic cancer	1.75e-06	2.36e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTEN—pancreatic cancer	1.74e-06	2.35e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CD44—pancreatic cancer	1.71e-06	2.32e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.7e-06	2.3e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—AKT1—pancreatic cancer	1.69e-06	2.29e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GCG—pancreatic cancer	1.64e-06	2.22e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	1.62e-06	2.19e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—HRAS—pancreatic cancer	1.62e-06	2.19e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SRC—pancreatic cancer	1.61e-06	2.18e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	1.61e-06	2.17e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	1.6e-06	2.16e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTGS2—pancreatic cancer	1.59e-06	2.15e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.58e-06	2.14e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—VEGFA—pancreatic cancer	1.57e-06	2.12e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PPARG—pancreatic cancer	1.56e-06	2.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—STAT3—pancreatic cancer	1.55e-06	2.1e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NRAS—pancreatic cancer	1.55e-06	2.1e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—AKT1—pancreatic cancer	1.55e-06	2.09e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—STK11—pancreatic cancer	1.54e-06	2.09e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PPARG—pancreatic cancer	1.53e-06	2.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MYC—pancreatic cancer	1.44e-06	1.95e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TGFB1—pancreatic cancer	1.44e-06	1.95e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—AKT1—pancreatic cancer	1.43e-06	1.93e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	1.43e-06	1.93e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	1.39e-06	1.88e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.39e-06	1.88e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTEN—pancreatic cancer	1.39e-06	1.88e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTGS2—pancreatic cancer	1.38e-06	1.87e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KRAS—pancreatic cancer	1.33e-06	1.8e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.33e-06	1.8e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	1.24e-06	1.68e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTGS2—pancreatic cancer	1.23e-06	1.67e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CA—pancreatic cancer	1.22e-06	1.66e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.21e-06	1.64e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTEN—pancreatic cancer	1.2e-06	1.63e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.2e-06	1.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—pancreatic cancer	1.18e-06	1.6e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HRAS—pancreatic cancer	1.13e-06	1.53e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—APOE—pancreatic cancer	1.08e-06	1.46e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTEN—pancreatic cancer	1.07e-06	1.45e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTEN—pancreatic cancer	1.05e-06	1.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKT1—pancreatic cancer	1e-06	1.35e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	9.8e-07	1.33e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	9.75e-07	1.32e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PPARG—pancreatic cancer	9.41e-07	1.27e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	8.57e-07	1.16e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	8.48e-07	1.15e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AKT1—pancreatic cancer	8e-07	1.08e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	7.57e-07	1.02e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	7.47e-07	1.01e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	7.4e-07	1e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	7.39e-07	1e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AKT1—pancreatic cancer	6.93e-07	9.38e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTEN—pancreatic cancer	6.46e-07	8.74e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AKT1—pancreatic cancer	6.19e-07	8.37e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AKT1—pancreatic cancer	6.04e-07	8.17e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	4.55e-07	6.16e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.72e-07	5.03e-06	CbGpPWpGaD
